Gujarat Themis Biosyn acquires MicroBiopharm to enhance capabilities
pre-market1 source ↓written by the desknot a recommendation
- in MicroBiopharm Japan
- 100% equity
Gujarat Themis Biosyn Limited has completed the acquisition of 100% equity in MicroBiopharm Japan for JPY 21.5 billion. This strategic move, funded through a mix of debt and equity, aims to enhance GTBL's fermentation capabilities and is expected to be EPS accretive. The existing management will continue to lead operations, ensuring a smooth transition.
Not investment advice. For informational purposes only.